CareDx (CDNA) Misses Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
CareDx, Inc. Reports Third Quarter 2015 Financial Results
November 11, 2015 4:05 PM ESTBRISBANE, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today reported financial results for the third quarter ended September 30, 2015.
Recent highlights:
Total revenues for the third quarter were $7.2 million, a year-over-year increase of 7% Significant progress on AlloSure, the company's transplant surveillance solution under development based on cfDNA technology: The DART clinical trial, an observational study designed to demonstrate the clinical performance characteristics of cell-free DNA... More